NYSE$UHS
Universal Health Services Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
UHS's net revenues increased and net income decreased during the fourth quarter of 2022.
Universal Health Services, Inc. reported a 5.2% increase in net revenues to $3.447 billion for the fourth quarter of 2022, compared to $3.275 billion in the fourth quarter of 2021. However, net income attributable to UHS decreased to $174.8 million, or $2.43 per diluted share, from $239.1 million, or $3.00 per diluted share, in the same period of the previous year. Adjusted net income attributable to UHS was $217.1 million, or $3.02 per diluted share, compared to $235.1 million, or $2.95 per diluted share, for the fourth quarter of 2021.
- Net revenues increased by 5.2% to $3.447 billion during Q4 2022.
- Net income attributable to UHS was $174.8 million, or $2.43 per diluted share, during Q4 2022.
- Adjusted net income attributable to UHS was $217.1 million, or $3.02 per diluted share, during Q4 2022.
- EBITDA net of NCI was $419.0 million during Q4 2022, as compared to $464.5 million during Q4 2021.
Headline financials
Revenue & EPS history
UHS · Revenue · Quarterly
$3.45B
Revenue by segment
UHS · $3.43B total across 2 segments · Q4 2022
- Acute Care Services$1.94B+5.6%56.5%
- Behavioral Health Services$1.49B+4.6%43.5%
Forward guidance
UHS projects net revenues between $14.044 billion and $14.314 billion and Adjusted EPS-diluted between $9.50 and $10.50 per share for the year ending December 31, 2023. The adjusted EBITDA net of NCI is expected to be between $1.662 billion and $1.753 billion.
Tailwinds
- Net revenues are estimated to be approximately $14.044 billion to $14.314 billion representing an increase of approximately 4.8% to 6.8% over our 2022 net revenues of approximately $13.399 billion.
- Adjusted EBITDA net of NCI is estimated to be approximately $1.662 billion to $1.753 billion, as compared to our 2022 Adjusted EBITDA net of NCI of $1.662 billion.
- Adjusted EPS-diluted range is estimated to be $9.50 per diluted share to $10.50 per diluted share, as compared to our adjusted net income attributable to UHS of $9.88 per diluted share for the year ended December 31, 2022, as calculated on the attached Supplemental Schedule.
Headwinds
- The 2023 forecasted amounts exclude the impact of future items, if applicable, that are nonrecurring or non-operational in nature including items such as pre-tax unrealized gains/losses resulting from changes in the market value of shares of certain equity securities.
- Our projected interest expense during 2023 is estimated to increase by approximately $71 million, or 56%, over the interest expense incurred during 2022.
- The increase is due primarily to increases in our projected average cost of borrowings, and aggregate average borrowings outstanding, pursuant to our revolving credit and tranche A term loan facilities.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+0.3%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+0.7%
Avg return
30 days after
49%
34 / 69 earnings
Positive
+17.5%
Q3 2022
Best reaction
-13.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -9.5% | -7.0% | -16.4% | |
| Q4 2025 | -5.5% | -1.0% | -9.9% | |
| Q3 2025 | +2.5% | +1.4% | +14.1% | |
| Q2 2025 | -0.2% | +3.3% | +7.3% | |
| Q1 2025 | -0.6% | +3.4% | +10.5% | |
| Q4 2024 | +3.3% | -3.8% | +3.4% | |
| Q3 2024 | -13.4% | -12.1% | -15.5% | |
| Q2 2024 | +10.6% | +17.3% | +25.8% | |
| Q1 2024 | +0.1% | +2.6% | +6.9% | |
| Q4 2023 | -1.6% | +4.1% | +11.0% | |
| Q3 2023 | -0.2% | -0.6% | +11.4% | |
| Q2 2023 | -4.6% | -6.5% | -12.3% | |
| Q1 2023 | +1.5% | +6.9% | -9.3% | |
| Q4 2022 | -9.1% | -13.5% | -15.5% | |
| Q3 2022 | +17.5% | +25.8% | +39.3% | |
| Q2 2022 | -1.5% | +1.3% | -5.7% | |
| Q1 2022 | -5.7% | -7.8% | -8.1% | |
| Q4 2021 | +8.6% | +8.7% | +11.1% | |
| Q3 2021 | -7.0% | -8.5% | -5.0% | |
| Q2 2021 | +4.2% | +5.1% | +1.6% | |
| Q1 2021 | +0.3% | +2.0% | +10.1% | |
| Q4 2020 | -9.1% | -6.2% | -2.0% | |
| Q3 2020 | +3.0% | +11.1% | +24.2% | |
| Q2 2020 | +0.9% | +1.7% | +0.2% | |
| Q1 2020 | +3.7% | -2.5% | +8.6% | |
| Q4 2019 | -5.3% | -2.7% | -34.3% | |
| Q3 2019 | -4.6% | -4.0% | -3.6% | |
| Q2 2019 | +10.9% | +11.6% | +4.7% | |
| Q1 2019 | -0.8% | -2.6% | -5.5% | |
| Q4 2018 | +3.9% | +2.7% | +0.1% | |
| Q3 2018 | -5.3% | -1.0% | +8.0% | |
| Q2 2018 | +9.3% | +9.3% | +12.0% | |
| Q1 2018 | -4.6% | -5.2% | -3.2% | |
| Q4 2017 | -1.3% | +5.3% | +0.7% | |
| Q3 2017 | -6.9% | -8.3% | -9.9% | |
| Q2 2017 | -9.2% | -10.3% | -12.6% | |
| Q1 2017 | -2.0% | -0.1% | -3.0% | |
| Q4 2016 | -0.9% | -0.8% | -0.8% | |
| Q3 2016 | +0.6% | -0.7% | +1.3% | |
| Q2 2016 | -4.4% | -5.2% | -12.1% | |
| Q1 2016 | +2.1% | — | — | |
| Q4 2015 | +2.4% | — | — | |
| Q3 2015 | +2.4% | — | — | |
| Q2 2015 | +2.1% | — | — | |
| Q1 2015 | -0.7% | — | — | |
| Q4 2014 | +3.8% | — | — | |
| Q3 2014 | -1.0% | — | — | |
| Q2 2014 | +6.8% | — | — | |
| Q1 2014 | +8.3% | — | — | |
| Q4 2013 | -2.6% | — | — | |
| Q3 2013 | +2.6% | — | — | |
| Q2 2013 | +3.3% | — | — | |
| Q1 2013 | +3.3% | — | — | |
| Q4 2012 | -0.0% | — | — | |
| Q3 2012 | -3.2% | — | — | |
| Q2 2012 | +4.8% | — | — | |
| Q1 2012 | -1.7% | — | — | |
| Q2 2011 | +2.0% | — | — | |
| Q4 2011 | +2.0% | — | — | |
| Q3 2011 | +3.8% | — | — | |
| Q1 2010 | +3.8% | — | — | |
| Q4 2010 | +3.8% | — | — | |
| Q1 2011 | +3.8% | — | — | |
| Q2 2010 | +5.0% | — | — | |
| Q3 2009 | +0.0% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q4 2009 | -0.3% | — | — | |
| Q2 2009 | -0.3% | — | — | |
| Q4 2008 | -0.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro